Pfizer, Ranbaxy Lipitor Generic Anticompetitive Agreement Complaint

May 22, 2020

With the high prices of US drugs, a popular medicine can be an enormous moneymaker for a pharmaceutical company. But the patents that give those companies exclusivity have a limited term, after which generics or bioequivalents can come on the market, driving prices downwards. The complaint for this antitrust class action alleges that a number of companies conspired to permit Pfizer, Inc. to retain its exclusive hold on the market for Lipitor, thus causing purchasers to pay higher prices for the drug.

Case Event File: Pfizer, Ranbaxy Lipitor Generic Anticompetitive Agreement Complaint

Related to: Pfizer, Ranbaxy Lipitor Generic Anticompetitive Agreement Class Action